MedTrace Logo

The First Therapeutic Intervention in Malignant Pleural Effusion Trial

NCT00896285 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2015-07-20

No results posted yet for this study

Summary

Fluid caused by cancer cells may accumulate in the lining of the lung. Draining the fluid with a chest tube may relieve pain and shortness of breath. To stop the fluid from coming back again, patients are given a medicine (talc) into the chest drain to seal up the space around the lung. This procedure is known as pleurodesis. This sometimes causes pain and discomfort, and the investigators do not know the best way of preventing this.

The investigators hope to find the best way to prevent pain during pleurodesis.

Conditions

  • Malignant Pleural Effusion
  • Pleural Effusion

Interventions

OTHER

Large bore chest drain + NSAID based analgesic regimen

Chest tube greater than 14 French size and ibuprofen.

OTHER

Small bore chest drain + NSAID based analgesic regimen

Chest tube less than or equal to 14 French size and ibuprofen.

OTHER

Large bore chest drain + opiate based analgesic regimen

Chest tube greater than 14 French size and morphine.

OTHER

Small bore chest drain + opiate based analgesic regimen

Chest tube less than or equal to 14 French size and morphine.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • RJO Davies, Dr. · Oxford Pleural Unit, Churchill Hospital, Oxford, England

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00896285 on ClinicalTrials.gov